Boceprevir: Phase III data

The double-blind, international Phase III HCV SPRINT-2 trial in 1,097 treatment-naïve patients with chronic HCV genotype 1 infection showed that both regimens of boceprevir plus PegIntron peginterferon alfa-2b and Rebetol ribavirin met the primary endpoint of a significantly greater proportion of patients achieving an SVR vs. placebo plus PegIntron and Rebetol. Specifically, 66% and 63% of patients in the 48-week and response-guided treatment groups achieved an SVR, respectively, vs. 38% for placebo plus PegIntron and Rebetol (p<0.0001 for both).

In non-African-American patients (n=938), 69% and 67% of patients in the 48-week and response-guided treatment groups achieved an SVR, respectively, vs. 40% for placebo plus PegIntron and Rebetol (p<0.0001 for both). In African-American patients (n=159), 53% and 42% of patients in the 48-week and response-guided treatment groups achieved an SVR, respectively, vs. 23% for placebo plus PegIntron and Rebetol (p=0.004 and p=0.044, respectively). ...